Navigation Links
Medarex Announces Ipilimumab Program Continues to Move Forward
Date:4/3/2008

Previously-Stated Guidance Remains Unchanged

PRINCETON, N.J., April 3, 2008 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) today issued the following statement in response to the announcement by Pfizer Inc that it was discontinuing its Phase 3 clinical trial of front-line treatment with Pfizer's single-agent anti-CTLA-4 antibody (tremelimumab) compared to chemotherapy in patients with advanced melanoma. Dr. Geoffrey M. Nichol, M.B.Ch.B., Senior Vice President, Product Development of Medarex, stated:

"While Pfizer's tremelimumab and Medarex's ipilimumab have a similar mechanism of action and have been considered by some as similar molecules, it is natural to attempt to draw parallels between the two molecules. However, we feel we need to make certain clarifications. First, the two antibodies are different molecules, and results from one antibody program may not be indicative of results from another program. The molecules are of different IgG antibody subclasses, administered at different doses and dosing schedules, and with different pharmacokinetic parameters.

Second, while, as previously reported, the results from the Phase 2 study under special protocol assessment did not meet the primary endpoint, the three studies in our Phase 2 program were suggestive of ipilimumab's potential for clinical anti-tumor activity based on the totality of the data and are under discussion with regulatory agencies.

Third, Medarex's ongoing ipilimumab Phase 3 program (study 024) for front- line treatment of advanced melanoma is different in design from the Pfizer trial, and at this time, it is too early to draw any clinical conclusions from the Pfizer announcement. In addition, a recent review of our ongoing 0
'/>"/>

SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
2. Medarex to Receive Milestone Payment from Amgen
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
8. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
9. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
10. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 24, 2013 3SBio ... the "Company"), a leading China ... and marketing biopharmaceutical products, announced today that, at ... the Company,s shareholders voted in favor of the ... agreement and plan of merger dated February 8, ...
(Date:5/23/2013)... Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) ... and Chief Executive Officer of Neurocrine Biosciences, will be presenting ... Care Conference in Boston.   The live presentation ... Time / 8:20 a.m. Pacific Time.  The presentation will be ... http://www.neurocrine.com . If you are unable ...
(Date:5/23/2013)... RIVER EDGE, N.J. , May 23, 2013 /PRNewswire/ ... ), a commercial stage medical device company that develops ... the successful completion of its rights offering.  In addition, ... company,s March 2011 warrants expired on May 17, 2013. ... proceeds of $3.0 million from the rights offering.   A ...
Breaking Medicine Technology:3SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 23SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 3Nephros Announces Completion of Rights Offering 2Nephros Announces Completion of Rights Offering 3Nephros Announces Completion of Rights Offering 4
... N.C., and ALISO VIEJO, Calif., Aug. 30 GlaxoSmithKline (NYSE: ... VRX ) announced today the U.S. Food and Drug ... (PDUFA) goal date for ezogabine* to 30 November 2010.  The ... The FDA has not yet completed the review of the ...
... ATLANTA, Aug. 30 Brothers blow the numbers ... seven short years ago and have never looked ... (Logo:   http://photos.prnewswire.com/prnh/20100817/INC5000LOGO ) (Logo: ... leading provider of low cost ultrasound systems in ...
Cached Medicine Technology:GSK and Valeant Announce New U.S. FDA PDUFA Goal Date for Ezogabine 2GSK and Valeant Announce New U.S. FDA PDUFA Goal Date for Ezogabine 3National Ultrasound Makes the Inc 5000 List for Third Year in a Row 2
(Date:5/25/2013)... On May 25, Voices Against Brain Cancer, ... comments on a new study by the Max Planck ... plasma into brain cancer treatment may help when dealing ... Science Daily article, physicists from the Max Planck ... the “synergistic effect of cold atmospheric plasma -- a ...
(Date:5/25/2013)... May 25, 2013 Dr. Farooq Ashraf, ... clinic in Dubai, has announced his practice’s adoption of ... the only FDA-cleared femtosecond laser proven with more than ... and precision of LASIK. , “We are happy to ... Femtosecond Laser at our Dubai LASIK practice,” Ashraf said ...
(Date:5/25/2013)... (PRWEB) May 25, 2013 The Slim Weight ... effectiveness and results. This is due to the highly sought ... patches. Slim weight patch offers an extra 2 months supply ... fitness goals and get the body you desire faster than ... Official Website , With Slim weight patch consumers can ...
(Date:5/25/2013)... (PRWEB) May 25, 2013 For ... than finals week. Increasingly, they are turning to ... awake and study. For more on this, go ... drug treatment facility, warns that students who pick ... are at risk for developing a physical and ...
(Date:5/25/2013)... Richmond, Virginia (PRWEB) May 25, 2013 ... bracelet that relieves pain in seconds for arthritis, tendinitis ... innovator in alternative pain relief products announced a ... seconds. The magnetic bracelet for pain relief is demonstrated ... for pain uses 5400 Gauss magnets and has customers ...
Breaking Medicine News(10 mins):Health News:Voices Against Brain Cancer Comments on Study that Shows Cold Plasma’s Success Against Brain Cancer Cells 2Health News:Atlanta Vision Clinic Acquires the Latest in Blade-Free Lasik Technology Bringing Dubai Patients the Intralase Method 2Health News:Slim Weight Patch Advanced Weight Loss System Offers Extra Two Month Supply and Membership for Maximum Weight Loss 2Health News:Addiction and Drug Abuse: Study Drug Adderall Abuse Spikes During Finals 2Health News:Magnetic bracelet relieves pain in seconds announces Superior Magnetics 2
... to relieve stress, a common cause of heart ... ... us think,of love and Valentine,s Day. This February, which also is National Heart,Awareness ... your heart. A healthy heart can be attained in a variety,of ways that ...
... PORTLAND, Ore. An Oregon Health & Science University Cancer ... the ability to predict if a mans prostate cancer is ... In order to make this discovery, researchers examined prostate cancer ... cancer patients. The researchers found that men whose tumors showed ...
... course of the presidential nomination campaign, some candidates health ... the phrase socialized medicine has been used to attack ... poll by the Harvard Opinion Research Program at the ... finds that Americans are split on whether a socialized ...
... National Board, KNOXVILLE, Tenn., Feb. 14 ... of Stacy Goldsholl, MD, as an,officer of its ... Medicine, is serving her second consecutive term as ... the premier medical society that,represents hospitalists. Hospital medicine ...
... (Nasdaq: DATA ), a technology company focused ... today reported that it will be,presenting at the ... at the Ritz Carlton in Laguna Niguel, California, ... on Wednesday afternoon,February 20th at 2:30 P.M., Pacific ...
... researchers from Europe and North America were given important ... national boundaries at a two-day training course in Croydon, ... Foundation as part of its Pan-European Clinical Trials (ECT) ... trials with a specific focus on the Euramos trial ...
Cached Medicine News:Health News:Healthy Heart, Healthy Home 2Health News:OHSU cancer institute researcher discovers new predictor of prostate cancer recurrence 2Health News:Poll finds Americans split by political party over views on socialized medicine 2Health News:Poll finds Americans split by political party over views on socialized medicine 3Health News:Stacy Goldsholl, MD, Re-elected to Board of Society of Hospital Medicine 2Health News:DATATRAK to Present at the Roth Capital Partners 20th Annual Orange County Stock Conference 2Health News:DATATRAK to Present at the Roth Capital Partners 20th Annual Orange County Stock Conference 3Health News:ESF's EMRC strengthens training course on clinical trials management 2
The design features of the Mini Lag Screw System simplify the screw fixation by reducing possible sources of error, reducing instrumentation, and decreasing the time of fixation....
... Supports the lower extremity for prepping before hip ... extremity procedures and particularly helpful for supporting the ... position. By holding the foot/ankle in an externally ... extension which helps eliminate the need for manual ...
... The Bio-Post and Washer System offers a ... soft tissue fixation in ligament repair or ... cancellous screw design provide maximum fixation in ... can be intraoperatively determined and the screw ...
... a patient during hip surgery. The Stulberg ... a patient during total hip and revision surgery. ... operating table utilizing the existing table adapters. ... to help prevent pressure points and are sealed ...
Medicine Products: